InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2023-10-16 | Josh Gottheimer(D-NJ05) | house | Purchase | $1,001 - $15,000 |
| 2023-09-15 | Josh Gottheimer(D-NJ05) | house | Sale | $1,001 - $15,000 |
| 2023-06-13 | Josh Gottheimer(D-NJ05) | house | Sale | $1,001 - $15,000 |
| 2020-10-16 | Josh Gottheimer(D-NJ05) | house | Purchase | $1,001 - $15,000 |
| 2020-09-15 | Josh Gottheimer(D-NJ05) | house | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Total Revenue, net | $1.61T-1.5% | $1.64T+6.1% | $1.54T | — | — |
| Cost of goods sold | $728.47B-9.4% | $803.63B+22.3% | $656.84B | — | $587.4M |
| Research and development | $115.38B+16.6% | $98.97B-5.0% | $104.19B | — | $101.2M |
| Selling, general and administrative | $716.98B+2.5% | $699.70B+6.6% | $656.64B | — | $616.3M |
| Intangible asset amortization | $21.29B+42.4% | $14.95B+20.8% | $12.38B | — | $13.9M |
| Goodwill impairment charge | $511.37B-0.0% | $511.40B | $0 | $0 | — |
| Total costs and expenses | $1.58T-25.7% | $2.13T+48.8% | $1.43T | — | $1.32B |
| Operating (loss) income | $28.41B+105.8% | -$493.37B-542.4% | $111.53B | — | — |
| Interest income | $20.04B+8.5% | $18.47B+7.4% | $17.20B | — | $11.9M |
| Interest expense | -$70.63B+18.1% | -$86.25B-67.9% | -$51.38B | — | -$49.6M |
| Other (expense) income, net | $3.94B+267.8% | -$2.35B-163.2% | $3.72B | — | — |
| (Loss) income before income taxes | -$18.24B+96.8% | -$563.50B-795.1% | $81.07B | — | $213.9M |
| (Benefit) provision for income taxes | -$11.29B+76.0% | -$47.03B-452.9% | $13.33B | — | — |
| Net (loss) income | -$6.94B+98.7% | -$516.47B-862.4% | $67.74B | — | $180.6M |
| Basic (in dollars per share) | -$90+98.7% | -$7K-892.9% | $850 | — | $2K |
| Diluted (in dollars per share) | -$90+98.7% | -$7K-902.4% | $840 | — | $2K |
| Basic (in shares) | $77.0M+0.4% | $76.7M-4.3% | $80.1M | — | $83.0M |
| Diluted (in shares) | $77.0M+0.4% | $76.7M-4.6% | $80.3M | — | $83.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
1 Value Stock to Research Further and 2 We Turn Down
Integra LifeSciences (IART) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Is This the Right Time to Hold IART Stock in Your Portfolio?
AxoGen (AXGN) Q1 Earnings Lag Estimates